Key clinical point: Tildrakizumab (Ilumya) significantly improved joint and skin manifestations in patients with psoriatic arthritis.
Major finding: At 24 weeks, more than 70% of patients treated with tildrakizumab versus 50% of those given placebo achieved an American College of Rheumatology (ACR) 20 response.
Study details: Randomized, double-blind, placebo-controlled, multiple-dose, phase 2b study to demonstrate the safety and efficacy of tildrakizumab in patients with active psoriatic arthritis.
Disclosures: The study was sponsored by Sun Pharmaceutical Industries. Dr. Mease has received research grants, consulting fees, speaker fees, or all, from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Galapagos, Genentech, Gilead, Janssen, Leo, Eli Lilly, Merck, Novartis, Pfizer, UCB, and Sun Pharmaceutical Industries.
Mease PJ et al. Ann Rheum Dis. Jun 2019;78(Suppl 2):77-9. Abstract LB0002, doi: 10.1136/annrheumdis-2019-eular.8669